{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:52:26Z","timestamp":1792511546150,"version":"4.5.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,7,2]],"date-time":"2020-07-02T00:00:00Z","timestamp":1593648000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,7,2]],"date-time":"2020-07-02T00:00:00Z","timestamp":1593648000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs R D"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1007\/s40268-020-00314-3","type":"journal-article","created":{"date-parts":[[2020,7,2]],"date-time":"2020-07-02T17:04:31Z","timestamp":1593709471000},"page":"189-195","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":72,"title":["Pexidartinib (TURALIO\u2122): The First FDA-Indicated Systemic Treatment for Tenosynovial Giant Cell Tumor"],"prefix":"10.1007","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5994-065X","authenticated-orcid":false,"given":"Shanada","family":"Monestime","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5075-8176","authenticated-orcid":false,"given":"Dovena","family":"Lazaridis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,2]]},"reference":[{"issue":"2","key":"314_CR1","doi-asserted-by":"publisher","first-page":"327","DOI":"10.4103\/ams.ams_161_18","volume":"8","author":"SK Shetty","year":"2018","unstructured":"Shetty SK, Hegde U, Agarwal G, Sreeshyla HS. Chondroid tenosynovial giant cell tumor of temporomandibular joint. Ann Maxillofac Surg. 2018;8(2):327\u20139.","journal-title":"Ann Maxillofac Surg"},{"issue":"1, Supplement","key":"314_CR2","doi-asserted-by":"publisher","first-page":"S91","DOI":"10.1016\/j.otsr.2016.11.002","volume":"103","author":"F Gouin","year":"2017","unstructured":"Gouin F, Noailles T. Localized and diffuse forms of tenosynovial giant cell tumor (formerly giant cell tumor of the tendon sheath and pigmented villonodular synovitis). Orthop Traumatol Surg Res. 2017;103(1, Supplement):S91\u2013S9797.","journal-title":"Orthop Traumatol Surg Res."},{"issue":"3","key":"314_CR3","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1073\/pnas.0507321103","volume":"103","author":"RB West","year":"2006","unstructured":"West RB, Rubin BP, Miller MA, Subramanian S, Kaygusuz G, Montgomery K, et al. A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells. Proc Natl Acad Sci USA. 2006;103(3):690\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"314_CR4","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1097\/PAS.0b013e31802b86f8","volume":"31","author":"JS Cupp","year":"2007","unstructured":"Cupp JS, Miller MA, Montgomery KD, Nielsen TO, O'Connell JX, Huntsman D, et al. Translocation and expression of CSF1 in pigmented villonodular synovitis, tenosynovial giant cell tumor, rheumatoid arthritis and other reactive synovitides. Am J Surg Pathol. 2007;31(6):970\u20136.","journal-title":"Am J Surg Pathol"},{"key":"314_CR5","unstructured":"Tenosynovial Giant Cell Tumor. https:\/\/rarediseases.org\/rare-diseases\/tenosynovial-giant-cell-tumor\/. 2017."},{"issue":"1","key":"314_CR6","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.ocl.2005.08.002","volume":"37","author":"O Ofluoglu","year":"2006","unstructured":"Ofluoglu O. Pigmented villonodular synovitis. Orthop Clin N Am. 2006;37(1):23\u201333.","journal-title":"Orthop Clin N Am"},{"issue":"6","key":"314_CR7","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1080\/17453674.2017.1361126","volume":"88","author":"MJL Mastboom","year":"2017","unstructured":"Mastboom MJL, Verspoor FGM, Verschoor AJ, Uittenbogaard D, Nemeth B, Mastboom WJB, et al. Higher incidence rates than previously known in tenosynovial giant cell tumors. Acta Orthop. 2017;88(6):688\u201394.","journal-title":"Acta Orthop"},{"key":"314_CR8","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s13569-018-0101-2","volume":"8","author":"N Giustini","year":"2018","unstructured":"Giustini N, Bernthal NM, Bukata SV, Singh AS. Tenosynovial giant cell tumor: case report of a patient effectively treated with pexidartinib (PLX3397) and review of the literature. Clin Sarcoma Res. 2018;8:14.","journal-title":"Clin Sarcoma Res."},{"issue":"2","key":"314_CR9","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/s11864-015-0385-x","volume":"17","author":"M Brahmi","year":"2016","unstructured":"Brahmi M, Vinceneux A, Cassier PA. Current systemic treatment options for tenosynovial giant cell tumor\/pigmented villonodular synovitis: targeting the CSF1\/CSF1R axis. Curr Treat Options Oncol. 2016;17(2):10.","journal-title":"Curr Treat Options Oncol"},{"issue":"6","key":"314_CR10","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1002\/cncr.26409","volume":"118","author":"PA Cassier","year":"2012","unstructured":"Cassier PA, Gelderblom H, Stacchiotti S, Thomas D, Maki RG, Kroep JR, et al. Efficacy of imatinib mesylate for the treatment of locally advanced and\/or metastatic tenosynovial giant cell tumor\/pigmented villonodular synovitis. Cancer. 2012;118(6):1649\u201355.","journal-title":"Cancer"},{"issue":"5","key":"314_CR11","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/S1470-2045(18)30143-8","volume":"19","author":"H Gelderblom","year":"2018","unstructured":"Gelderblom H, Cropet C, Chevreau C, Boyle R, Tattersall M, Stacchiotti S, et al. Nilotinib in locally advanced pigmented villonodular synovitis: a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2018;19(5):639\u201348.","journal-title":"Lancet Oncol"},{"issue":"10197","key":"314_CR12","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/S0140-6736(19)30764-0","volume":"394","author":"WD Tap","year":"2019","unstructured":"Tap WD, Gelderblom H, Palmerini E, Desai J, Bauer S, Blay JY, et al. Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial. Lancet. 2019;394(10197):478\u201387.","journal-title":"Lancet"},{"key":"314_CR13","unstructured":"TURALIO (pexidartinib) [package insert]. Basking Ridge: Daiichi Sankyo, Inc; 2019."},{"issue":"5","key":"314_CR14","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1056\/NEJMoa1411366","volume":"373","author":"WD Tap","year":"2015","unstructured":"Tap WD, Wainberg ZA, Anthony SP, Ibrahim PN, Zhang C, Healey JH, et al. Structure-guided blockade of CSF1R kinase in tenosynovial giant-cell tumor. N Engl J Med. 2015;373(5):428\u201337.","journal-title":"N Engl J Med"},{"key":"314_CR15","unstructured":"TURALIOTM (pexidartinib) Academy of Managed Care Pharmacy (AMCP) v4.0 Formulary Submission Dossier. Daiichi-Sankyo; 2019."}],"container-title":["Drugs in R&D"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-020-00314-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40268-020-00314-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-020-00314-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T23:16:34Z","timestamp":1625181394000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40268-020-00314-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,2]]},"references-count":15,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["314"],"URL":"https:\/\/doi.org\/10.1007\/s40268-020-00314-3","relation":{},"ISSN":["1174-5886","1179-6901"],"issn-type":[{"value":"1174-5886","type":"print"},{"value":"1179-6901","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,2]]},"assertion":[{"value":"2 July 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This study was not funded.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors declare that they have no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}